N/A N=30 HORIZON CE Pivotal Study to Treat Abdominal Aortic Aneurysm
Infrarenal Abdominal Aortic Aneurysms · Aortoiliac Aneurysms
Primary: Safety Endpoint: Major Adverse Events (MAEs) — 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=30 Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
Marfan Syndrome
Primary: Central Aortic Distensibility by MRI — 3.7; 4.7; 5.7; 5.1 (mmHg ^ -1) x 10 ^ -3
Phase 3 N=40 Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Marfan Syndrome
Primary: Aortic Biophysical Properties - Pulse Wave Velocity — -1.15; -0.22 change in meters/second
Phase 4 N=259 GORE EXCLUDER® Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms
Aortic Aneurysm, Abdominal
Primary: Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure — 9; 31 participants — p=<0.001
N/A N=210 DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial
Cerebral Aneurysm
Primary: Major Recurrence of Lesion or Presence of Residual Aneurysm — 26; 20 Participants
Phase 2 N=82 Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants
Phase 2 N=35 Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms
Aortic Aneurysm, Abdominal
Primary: Time to First Major Adverse Event Experienced by Subjects From the Time of Treatment Through 1 Year — 84.0 days — p=0.003
Phase 1 N=43 A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants Without a Device Related Adverse Events Within 1 Month of the Study Procedure. — 36 Participants
N/A N=49 Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With Abdominal Aortic Aneurysms (AAA)
Abdominal Aortic Aneurysms
Primary: Number of Participants With Successful Exclusion of Abdominal Aortic Aneurysm — 49 participants' AAA
N/A N=333 Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Abdominal Aortic Aneurysm (AAA)
Primary: Major Adverse Events at 30 Days — 4; 1; 2 Participants
Phase 4 N=14 ABRA Abdominal Closure System in Open Abdomen Management
Open Abdomen
Primary: Primary Closure Rate — 75; 67 % of participants
N/A N=10 Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair
Problem With Vision Blindness · Intraocular Pressure · Ischemic Optic Neuropathy
Primary: Right Intraocular Pressure During Various Event Intervals in Open Abdominal Aortic Aneurysm Surgery. — 16.9; 13.8; 14.6; 13.5 mm Hg — p=<0.001
N/A N=120 The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms
Wide-neck, Saccular Intracranial Aneurysms
Primary: Number of Participants With Raymond Class I Complete Obliteration at 12 Months — 98 Participants
N/A N=150 European (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysms
Primary: Number of Participants With Major Adverse Events (MAE) Through 30 Days — 0 participants
N/A N=190 A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)
Abdominal Aortic Aneurysm
Primary: Number of Participants With Incidence of MAE (Major Adverse Events) Based Upon a Composite MAE Rate — 20 Participants — p=0.47